Compare Mesoblast Limited (MESO) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Banco Santander SA — how do they compare? Mesoblast Limited trades at $14.24 (market cap $1.75B), while Banco Santander SA trades at $13.5 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 110.2× Mesoblast Limited's market cap, and Banco Santander SA pays a 2.06% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Banco Santander SA for 55 Days on average.
| MESO | SAN | |
|---|---|---|
Market Cap | $1.75B | $192.86B |
Volume | 239,027 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $20.96 | $15.05 |
52-Week Low | $13.19 | $9.65 |
Typical Hold Time | 15 Days | 55 Days |
Enterprise Value | $1.83B | $360.86B |
Dividend Yield | — | 2.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Banco Santander (SAN) trades at $13.44, down 1.65% today amid bearish technical signals. The stock shows mixed earnings performance with Q1 2026 beating estimates but Q2 missing. Fundamentals remain solid with 26.25% net income margin and 16.07% ROE, though cash flow trends show recent weakness. Recent developments include the completed Webster acquisition expanding U.S. presence and record Q2 2026 profits driven by digital transformation.
SAN presents a value opportunity with reasonable P/E of 13.55 and strong analyst support (64% buy ratings), but faces risks from declining operating cash flows and high debt levels. The technical bearish signal suggests near-term pressure, while fundamental strength supports long-term potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
